An FDA advisory panel narrowly recommended expanding compounding of certain unapproved peptides, including support for epitalon while rejecting compounding of emideltide, in tightly contested votes that could increase access to widely used non-standard-of-care products. The decision follows additional panel recommendations on other peptides, moving the FDA toward a potential update of how pharmacies can manufacture these compounds under Section 503A. While advisory outcomes are non-binding, the FDA’s final rulemaking and enforcement approach will determine whether the U.S. supply chain sees broad new compounded peptide availability. For investors and developers, the ruling adds pressure to regulators to clarify evidentiary requirements and manufacturing expectations for substances that have not demonstrated FDA-approved safety and efficacy. It also increases the potential for off-label clinical use and downstream demand for companion testing and monitoring services.